Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-1 adrenergic receptor family consists of three highly homologous G protein-coupled receptor subtypes: alpha-1A, alpha-1B, and alpha-1D. These receptors are primarily coupled to the Gq/11 heterotrimeric G protein, and their activation by endogenous catecholamines (norepinephrine and epinephrine) stimulates the phospholipase C pathway, leading to intracellular calcium mobilization and subsequent smooth muscle contraction. They are widely distributed throughout the body, with high expression in vascular smooth muscle, the prostate, and the bladder neck. Consequently, they play a critical role in cardiovascular homeostasis by regulating blood pressure through vasoconstriction, as well as in the regulation of urinary flow. Therapeutically, alpha-1 adrenergic receptor antagonists (alpha-blockers) are widely used to treat benign prostatic hyperplasia by relaxing prostatic smooth muscle, and to manage hypertension by inducing vasodilation. Conversely, alpha-1 agonists are utilized as vasopressors to treat hypotension and shock, and as nasal decongestants.
Drugs targeting the alpha-1 adrenergic receptor family act either as agonists or antagonists. Agonists (such as phenylephrine and midodrine) bind to and activate the receptors, which are coupled to Gq proteins. This activation stimulates phospholipase C (PLC), leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), which increases intracellular calcium levels and causes smooth muscle contraction (vasoconstriction). Antagonists (such as doxazosin and tamsulosin) block the binding of endogenous catecholamines (norepinephrine and epinephrine) to these receptors, preventing Gq-mediated signaling, which results in smooth muscle relaxation, vasodilation, and decreased peripheral resistance.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-1 adrenergic receptor family (ADRA1).